In 2025, the biopharmaceutical industry in Hefei, Anhui province, crossed the 100-billion-yuan ($14.48 billion) revenue threshold, supported by an ecosystem of more than 1,000 industrial chain enterprises.

The robust growth is attributed to Hefei's forward-looking industrial planning, collaborative innovation mechanisms, and continuously refined supporting policies. Local authorities, research institutions, enterprises, capital providers, and market entities have forged close partnerships, laying a solid foundation for technological R&D, achievement transformation, and industrial expansion.

With a 72% spike in Class III medical device approvals, Hefei outpaced all other cities in Anhui province for new healthcare product certifications last year. A string of innovative breakthroughs have been successfully commercialized, driving the entire industry's ascent to the mid-to-high end of the global value chain.

In constructing its innovation ecosystem, Hefei has developed a streamlined operational framework that bridges technological achievement, investment resources, and industrial application. The framework has facilitated the successful incubation of eight key enterprises, which have generated over 20 million yuan in output.

The city has also established specialized industry platforms, including National Healthcare Big Data Industrial Park and Pharmaceutical Valley Industrial Park, and launched Anhui's first pilot zone focusing on translating biomedical and biopharmaceutical research outcomes into market-ready applications.

Hefei has formed a comprehensive full-life-cycle support system for local companies. Moving forward, the city will advance high-quality, globally oriented development of the sector through financial support, industrial cluster enhancement, institutional innovation, and application scenario exploration.